Alligator is a biotechnology company that has historically focused on tumor‑directed immuno‑oncology. Following a strategic refocus, Alligator is prioritizing the value of its economic interest in HLX22, an anti‑HER2 monoclonal antibody being developed by Shanghai Henlius Biotech Inc., from which Alligator is entitled to a share of revenues without incurring development costs. The Company has discontinued further internal development of mitazalimab and is seeking to out‑license or divest the asset.
Founded in 2001, Alligator is headquartered at Medicon Village in Lund, Sweden, and is listed on Nasdaq Stockholm under the ticker ATORX.